Xencor doses first patient in phase 1 clinical trial of XmAb14045
Xencor has dosed the first patient in a Phase 1 clinical trial of XmAb14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
Click on this link for more information.
